Patent intelligence · US
US 11535851
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
Patent details — US 11535851
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 27, 2022
- Expiration
- Dec 22, 2042
- Applicant
- Benitec IP Holdings Inc.
- Claims
- 23
- CPC classes
- A61K, A61K31/513, A61K31/522, A61K31/675
Quick answer
US 11535851 (Reagents for treatment of hepatitis B virus (HBV) infection and use thereof) is held by Benitec IP Holdings Inc.. Status: granted. Granted Dec 27, 2022. Expires Dec 22, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Benitec IP Holdings Inc.
- Grant date
- Expiration
- Claims
- 23
- CPC classes
- A61K, A61K31/513, A61K31/522, A61K31/675, A61K38/21, A61P
More from Benitec IP Holdings Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11932852
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 11234994
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 11142765
Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
granted -
US 10898505
Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
granted -
US 10000753
Age-related macular degeneration treatment
granted -
US 9518260
Pain treatment
granted -
US 9410154
HBV treatment
granted
Frequently asked questions
What is US patent 11535851?
US 11535851 (Reagents for treatment of hepatitis B virus (HBV) infection and use thereof) is held by Benitec IP Holdings Inc.. Status: granted. Granted Dec 27, 2022. Expires Dec 22, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11535851?
Benitec IP Holdings Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.
When does US 11535851 expire?
Our index shows an expiration date of Dec 22, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.